| Literature DB >> 25761477 |
Chae-Seon Hong1, Dongryul Oh1, Sang Gyu Ju1, Yong Chan Ahn1, Jae Myoung Noh1, Kwangzoo Chung1, Jin Sung Kim1, Tae-Suk Suh2.
Abstract
PURPOSE: The purpose of this study was to investigate the dosimetric benefits and treatment efficiency of carotid-sparing TomoHelical 3-dimensional conformal radiotherapy (TH-3DCRT) for early glottic cancer.Entities:
Keywords: Carotid sparing; Early glottic cancer; Intensity-modulated radiotherapy; TomoHelical three-dimensional conformal radiotherapy
Mesh:
Year: 2015 PMID: 25761477 PMCID: PMC4720070 DOI: 10.4143/crt.2014.265
Source DB: PubMed Journal: Cancer Res Treat ISSN: 1598-2998 Impact factor: 4.679
Dose constraints for inverse planning
| Structure | Constraint |
|---|---|
| PTV | D95 ≥ 67.5 Gy |
| Spinal cord | Dmax ≤ 45 Gy |
| Carotid artery | V30 ≤ 20% |
| V10 ≤ 50% |
PTV, planning target volume; Dx, dose received by x% of the volume; Dmax, maximum dose; VD, the percentage of the organ volume that received D Gy or more.
Fig. 1.An axial view of isodose distributions at the target center for each of the four treatment plans and a single representative patient. (A) Two-field 3-dimensional conformal radiotherapy (2F-3DCRT). (B) Three-field intensity-modulated radiation therapy. (C) TomoHelical IMRT. (D) TomoHelical 3DCRT. Under 2F-3DCRT, the high-dose region that received the prescription dose was widely distributed over the carotid artery. Under the other three plans, the high-dose region did not include the carotid artery.
Comparisons of dosimetric characteristics and delivery efficiencies for different treatment techniques
| Parameter | 2F-3DCRT | 3F-IMRT | TH-IMRT | TH-3DCRT | p-value | ||
|---|---|---|---|---|---|---|---|
| 2F-3DCRT vs. TH-3DCRT | 3F-IMRT vs. TH-3DCRT | TH-IMRT vs. TH-3DCRT | |||||
| PTV | |||||||
| CI | 0.32 | 0.65 | 0.64 | 0.63 | 0.01[ | 0.83 | 0.39 |
| (0.3-0.35) | (0.62-0.67) | (0.60-0.68) | (0.60-0.67) | ||||
| HI | 1.06 | 1.09 | 1.05 | 1.05 | 0.39 | 0.01[ | > 0.99 |
| (1.05-1.07) | (1.08-1.10) | (1.05-1.06) | (1.048-1.063) | ||||
| Carotid artery | |||||||
| V35 (%) | 33.88 | 0.30 | 0.00 | 0.00 | 0.01[ | 0.01[ | > 0.99 |
| (20.44-41.36) | (0.05-0.30) | (0.00-0.00) | (0.00-0.00) | ||||
| V50 (%) | 18.48 | 0.00 | 0.00 | 0.00 | 0.01[ | > 0.99 | > 0.99 |
| (9.01-25.15) | (0.00-0.00) | (0.00-0.00) | (0.00-0.00) | ||||
| V63 (%) | 7.97 | 0.00 | 0.00 | 0.00 | 0.01[ | > 0.99 | > 0.99 |
| (3.97-13.17) | (0.00-0.00) | (0.00-0.00) | (0.00-0.00) | ||||
| Dmax (%) | 69.82 | 38.71 | 29.23 | 30.31 | 0.01[ | 0.01[ | 0.09 |
| (69.23-70.41) | (35.55-43.52) | (26.37-32.28) | (27.53-34.15) | ||||
| Spinal cord | |||||||
| Dmax (%) | 2.58 | 28.05 | 24.86 | 26.76 | 0.01[ | 0.97 | 0.01[ |
| (2.38-3.55) | (27.03-28.77) | (23.48-27.52) | (24.76-29.42) | ||||
| Planning time (min) | 5.85 | 45.48 | 35.30 | 7.10 | 0.01[ | 0.01[ | 0.01[ |
| (5.50-6.25) | (40.65-48.28) | (32.91-40.78) | (6.35-8.40) | ||||
| Delivery time (min) | 2.06 | 2.48 | 2.90 | 2.86 | 0.01[ | 0.01[ | > 0.99 |
| (1.99-2.11) | (2.45-2.51) | (2.81-2.97) | (2.73-3.00) | ||||
| Pretreatment dosimetric QA | × | ○ | ○ | × | - | - | - |
Values are presented as median (interquartile range). 2F-3DCRT, 2-field 3-dimensional conformal radiotherapy; 3F-IMRT, 3-field intensity-modulated radiation therapy; TH-IMRT, TomoHelical IMRT; TH-3DCRT, TomoHelical 3DCRT; PTV, planning target volume; CI, conformity index; HI, homogeneity index; VD, the percentage of the organ volume that received D Gy or more; Dmax, maximum dose; QA, quality assurance.
Statistically significant.
Fig. 2.This figure shows the mean dose-volume histogram (10 patients) for the carotid artery, including results for each of the four treatment plans that were investigated. In our treatment-planning simulations, the normalized volume of the carotid artery that received in excess of 30 Gy was the lowest using TomoHelical intensity-modulated radiation therapy (TH-IMRT), the second-lowest using TomoHelical 3-dimensional conformal radiotherapy (TH-3DCRT), the third-lowest using 3-field IMRT (3F-IMRT), and the highest using 2-field 3DCRT (2F-3DCRT).